CIK 0001817713
- Large accelerated filer
Janux Therapeutics, Inc.
Sign in to watch- Ticker
- JANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822289112
- Phone
- +1 858-751-4493
- Business address
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-02 | DiRaimondo Thomas Chief Scientific Officer | Grant or award | +24,000 | 129,719 | ||
| 2025-01-02 | DiRaimondo Thomas Chief Scientific Officer | Grant or award · Stock option (right to buy) | +84,000 | 84,000 | ||
| 2025-01-02 | Dobek Maria Vice President, Accounting | Grant or award | +14,000 | 14,001 | ||
| 2025-01-02 | Dobek Maria Vice President, Accounting | Grant or award · Stock option (right to buy) | +31,500 | 31,500 | ||
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Grant or award | +18,000 | 95,473 | ||
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −2,922 | $53.76 | $157K | 92,551 |
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −5,768 | $54.51 | $314K | 86,783 |
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −3,444 | $55.76 | $192K | 83,339 |
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −1,000 | $56.78 | $57K | 82,339 |
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −200 | $57.37 | $11K | 82,139 |
| 2025-01-02 | Meyer Andrew Hollman Chief Business Officer | Grant or award · Stock option (right to buy) | +63,000 | 63,000 | ||
| 2024-12-24 | Campbell David Alan President and CEO | Sale 10b5-1 | −25,000 | $56.19 | $1.4M | 217,054 |
| 2024-12-19 | Meyer Andrew Hollman Chief Business Officer | Option exercise | +9,880 | $20.24 | $200K | 77,472 |
| 2024-12-19 | Meyer Andrew Hollman Chief Business Officer | Option exercise | +1 | $14.02 | $14 | 77,473 |
| 2024-12-19 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) | −9,880 | 96,870 | ||
| 2024-12-19 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) | −1 | 89,999 | ||
| 2024-12-03 | Campbell David Alan President and CEO | Sale 10b5-1 | −15,000 | $67.00 | $1.0M | 242,054 |
| 2024-11-25 | Campbell David Alan President and CEO | Sale 10b5-1 | −18,281 | $51.43 | $940K | 263,773 |
| 2024-11-25 | Campbell David Alan President and CEO | Sale 10b5-1 | −6,719 | $52.04 | $350K | 257,054 |
| 2024-11-05 | Gujrathi Sheila Director | Other acquisition | +4,611 | 115,139 |
Page 6 of 15 · 294 trades